DE60313603D1 - Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung - Google Patents

Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung

Info

Publication number: DE60313603D1
Authority: DE; Germany
Prior art keywords: long; acute; pharmaceutical combination; benigner; harn
Prior art date: 2002-04-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE60313603T

Other languages

English (en)

Other versions

DE60313603T2 (de

Inventor

Wolfgang Baiker

Ludwig Mehlburger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Original Assignee

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-24

Filing date

2003-04-17

Publication date

2007-06-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60313603(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de

2002-04-25 Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de

2003-04-17 Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG

2007-06-14 Application granted granted Critical

2007-06-14 Publication of DE60313603D1 publication Critical patent/DE60313603D1/de

2008-01-03 Publication of DE60313603T2 publication Critical patent/DE60313603T2/de

2023-04-18 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

DE60313603T 2002-04-24 2003-04-17 Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung Revoked DE60313603T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE2002118392 DE10218392A1 (de)	2002-04-24	2002-04-24	Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE10218392		2002-04-24
DE2002118611 DE10218611A1 (de)	2002-04-25	2002-04-25	Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie
DE10218611		2002-04-25
PCT/EP2003/004034 WO2003090753A1 (en)	2002-04-24	2003-04-17	Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Publications (2)

Publication Number	Publication Date
DE60313603D1 true DE60313603D1 (de)	2007-06-14
DE60313603T2 DE60313603T2 (de)	2008-01-03

Family

ID=29271571

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60313603T Revoked DE60313603T2 (de)	2002-04-24	2003-04-17	Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung

Country Status (22)

Country	Link
US (2)	US20030225118A1 (de)
EP (2)	EP1743656A3 (de)
JP (1)	JP2005524693A (de)
CN (1)	CN1646135A (de)
AT (1)	ATE361075T1 (de)
AU (1)	AU2003227643A1 (de)
BR (1)	BR0309435A (de)
CA (1)	CA2479992A1 (de)
CY (1)	CY1107674T1 (de)
DE (1)	DE60313603T2 (de)
DK (1)	DK1501517T3 (de)
EA (1)	EA008377B1 (de)
ES (1)	ES2287474T3 (de)
HR (1)	HRP20040994A2 (de)
IL (1)	IL163976A0 (de)
MX (1)	MXPA04010408A (de)
NO (1)	NO20044333L (de)
NZ (1)	NZ536514A (de)
PL (1)	PL371430A1 (de)
PT (1)	PT1501517E (de)
RS (1)	RS92304A (de)
WO (1)	WO2003090753A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA008377B1 (ru) *	2002-04-24	2007-04-27	Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг	Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии
RU2006119331A (ru) *	2003-11-03	2007-12-27	БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE)	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
KR101195165B1 (ko) *	2003-11-14	2012-10-29	가부시키가이샤 한도오따이 에네루기 켄큐쇼	표시장치의 제조 방법
WO2006055659A2 (en) *	2004-11-15	2006-05-26	Smithkline Beecham Corporation	Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) *	2010-06-30	2012-01-11	北京润德康医药技术有限公司	一种复方制剂及其制备方法
WO2012110092A1 (en)	2011-02-17	2012-08-23	Synthon Bv	Tamsulosin derivatives
WO2012162776A1 (pt) *	2011-06-03	2012-12-06	Eurofarma Laboratórios S.A	Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en)	2012-02-20	2013-08-29	Synthon Bv	A fixed dose pharmaceutical formulation
US10596127B2 (en)	2013-03-14	2020-03-24	Wellesley Pharmaceuticals, Llc	Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) *	2013-08-12	2021-01-12	Ems S/A.	Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (de)	2014-05-26	2015-12-02	Galenicum Health S.L.	Pharmazeutische zusammensetzungen mit einem wirkstoff
KR20180066113A (ko) *	2015-09-30	2018-06-18	웰즐리 파마슈티컬스 엘엘씨	배뇨 빈도 감소용 조성물, 제조 방법 및 용도
US10172910B2 (en) *	2016-07-28	2019-01-08	Nymox Corporation	Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) *	2021-10-14	2023-04-18	上海汇伦医药股份有限公司	一种药物组合物及其用途
WO2024213090A1 (zh) *	2023-04-13	2024-10-17	上海汇伦医药股份有限公司	一种双重释放制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5391825A (en) *	1980-02-08	1995-02-21	Yamanouchi Pharmaceutical Co., Ltd.	Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en)	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Sulfamoyl-substituted phenetylamine derivative and its preparation
IL74365A (en)	1984-02-27	1990-07-26	Merck & Co Inc	17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US4760071A (en)	1984-02-27	1988-07-26	Merck & Co., Inc.	17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4772475A (en)	1985-03-08	1988-09-20	Yamanouchi Pharmaceutical Co., Ltd.	Controlled-release multiple units pharmaceutical formulation
DE3888994T2 (de)	1987-04-03	1994-11-03	Merck & Co Inc	Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE3888378T2 (de)	1987-04-03	1994-09-29	Merck & Co Inc	Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
IL101243A (en) *	1991-03-20	1999-12-22	Merck & Co Inc	Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
TW369521B (en)	1993-09-17	1999-09-11	Smithkline Beecham Corp	Androstenone derivative
TW382595B (en)	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) *	1999-02-16	2002-07-23	Upsher-Smith Laboratories, Inc.	Method for treating benign prostate hyperplasia
WO2001021167A1 (en) *	1999-09-22	2001-03-29	Merck & Co., Inc.	Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
EA008377B1 (ru) *	2002-04-24	2007-04-27	Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг	Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии

2003
- 2003-04-17 EA EA200401340A patent/EA008377B1/ru not_active IP Right Cessation
- 2003-04-17 AU AU2003227643A patent/AU2003227643A1/en not_active Abandoned
- 2003-04-17 RS YU92304A patent/RS92304A/sr unknown
- 2003-04-17 EP EP06122312A patent/EP1743656A3/de not_active Withdrawn
- 2003-04-17 MX MXPA04010408A patent/MXPA04010408A/es active IP Right Grant
- 2003-04-17 EP EP03725053A patent/EP1501517B1/de not_active Revoked
- 2003-04-17 PT PT03725053T patent/PT1501517E/pt unknown
- 2003-04-17 IL IL16397603A patent/IL163976A0/xx unknown
- 2003-04-17 BR BR0309435-9A patent/BR0309435A/pt not_active IP Right Cessation
- 2003-04-17 DK DK03725053T patent/DK1501517T3/da active
- 2003-04-17 NZ NZ536514A patent/NZ536514A/en unknown
- 2003-04-17 ES ES03725053T patent/ES2287474T3/es not_active Expired - Lifetime
- 2003-04-17 DE DE60313603T patent/DE60313603T2/de not_active Revoked
- 2003-04-17 AT AT03725053T patent/ATE361075T1/de active
- 2003-04-17 CN CNA038089300A patent/CN1646135A/zh active Pending
- 2003-04-17 PL PL03371430A patent/PL371430A1/xx not_active Application Discontinuation
- 2003-04-17 JP JP2003587387A patent/JP2005524693A/ja active Pending
- 2003-04-17 HR HR20040994A patent/HRP20040994A2/hr not_active Application Discontinuation
- 2003-04-17 WO PCT/EP2003/004034 patent/WO2003090753A1/en not_active Ceased
- 2003-04-17 CA CA002479992A patent/CA2479992A1/en not_active Abandoned
- 2003-04-24 US US10/422,509 patent/US20030225118A1/en not_active Abandoned
2004
- 2004-10-12 NO NO20044333A patent/NO20044333L/no not_active Application Discontinuation
2007
- 2007-04-06 US US11/697,470 patent/US20070197666A1/en not_active Abandoned
- 2007-06-14 CY CY20071100794T patent/CY1107674T1/el unknown

Also Published As

Publication number	Publication date
ES2287474T3 (es)	2007-12-16
PL371430A1 (en)	2005-06-13
PT1501517E (pt)	2007-05-31
BR0309435A (pt)	2005-02-15
WO2003090753A1 (en)	2003-11-06
EP1743656A2 (de)	2007-01-17
EP1743656A3 (de)	2007-03-07
IL163976A0 (en)	2005-12-18
DE60313603T2 (de)	2008-01-03
ATE361075T1 (de)	2007-05-15
EP1501517B1 (de)	2007-05-02
HRP20040994A2 (en)	2005-02-28
MXPA04010408A (es)	2005-02-17
RS92304A (sr)	2006-10-27
DK1501517T3 (da)	2007-06-11
CY1107674T1 (el)	2013-04-18
CN1646135A (zh)	2005-07-27
CA2479992A1 (en)	2003-11-06
NO20044333L (no)	2004-11-09
WO2003090753A8 (en)	2004-11-04
EA200401340A1 (ru)	2005-06-30
JP2005524693A (ja)	2005-08-18
AU2003227643A1 (en)	2003-11-10
EP1501517A1 (de)	2005-02-02
EA008377B1 (ru)	2007-04-27
US20070197666A1 (en)	2007-08-23
US20030225118A1 (en)	2003-12-04
NZ536514A (en)	2006-11-30

Publication	Publication Date	Title
DE60313603D1 (de)	2007-06-14	Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
DE60023982D1 (de)	2005-12-22	System zur Behandlung von benigner Prostatahyperplasie
ATE208210T1 (de)	2001-11-15	Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
ATE501722T1 (de)	2011-04-15	Therapeutische behandlung androgenrezeptorbedingter leiden
ATE242238T1 (de)	2003-06-15	Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DK0971713T3 (da)	2003-09-22	Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
EP1364659A4 (de)	2006-03-29	Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
CY1109650T1 (el)	2014-08-13	Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
ATE362374T1 (de)	2007-06-15	Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE281845T1 (de)	2004-11-15	Kombinationstherapie enthaltend bestrahlung und einen cox-2 hemmer in der behandlung von neoplasie
EP1320376A4 (de)	2005-06-15	Behandlung von prostatakrebs
DE60011794D1 (de)	2004-07-29	Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
DE69303919D1 (de)	1996-09-12	Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
EP1441761A4 (de)	2004-12-29	Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE211921T1 (de)	2002-02-15	Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
DE60214207D1 (de)	2006-10-05	Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE250580T1 (de)	2003-10-15	Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EA200401100A1 (ru)	2005-04-28	1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
ATE302009T1 (de)	2005-09-15	Ubichinon qn zur behandlung von migräneschmerzen
ATE291425T1 (de)	2005-04-15	R-eliprodil zur behandlung von glaucoma
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
TR199701613T1 (xx)	1998-04-21	Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
DE69711422D1 (de)	2002-05-02	Verwendung von (r)-verapamil als medizin zur behandlung von angina
ECSP982362A (es)	1998-12-22	Compuestos de quinolina y quinazolina utiles en terapia

Legal Events

Date	Code	Title	Description
2008-04-24	8363	Opposition against the patent
2009-10-29	8331	Complete revocation